Dasiglucagon
FDA-approved ready-to-use glucagon analog for severe hypoglycemia (Zegalogue).
What it's for
FDA-approved ready-to-use glucagon analog for severe hypoglycemia (Zegalogue).
What it's for
Dasiglucagon is a stable glucagon analog formulated for ready-to-use injection without reconstitution. It treats severe hypoglycemia in people with diabetes when they cannot take oral carbohydrates safely.
What it does for the body
It treats severe hypoglycemia in people with diabetes when they cannot take oral carbohydrates safely. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It activates hepatic glucagon receptors (lock-and-key landing spots on cells), stimulating glycogenolysis and raising blood glucose. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Dasiglucagon has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Dasiglucagon — FDA.gov search
- ClinicalTrials.gov search: Dasiglucagon — U.S. clinical trials registry
- Drugs@FDA search: Dasiglucagon — FDA drug database (if approved)
- PubMed search: Dasiglucagon — NCBI PubMed
- PubMed Central search: Dasiglucagon — NCBI PMC